ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

由 Sullivan, Ivana, Planchard, David
發表在 Ther Adv Med Oncol (2016)

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

由 Sullivan, Ivana, Planchard, David
發表在 J Thorac Dis (2016)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

由 Sullivan, Ivana, Planchard, David
發表在 Front Med (Lausanne) (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

由 Mezquita, Laura, Planchard, David
發表在 Cancer Manag Res (2018)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

由 Sullivan, Ivana, Planchard, David
發表在 Ther Adv Respir Dis (2016)

Oncogene addiction and immune escape: friends or foes?

由 Abdayem, Pamela, Planchard, David
發表在 Ann Transl Med (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

由 Abdayem, Pamela, Planchard, David
發表在 Transl Lung Cancer Res (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

由 Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David
發表在 Ther Adv Respir Dis (2019)

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

由 Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun
發表在 Front Oncol (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

由 Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin
發表在 Cancer Manag Res (2021)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

由 Schernberg, Antoine, Mezquita, Laura, Boros, Angela, Botticella, Angela, Caramella, Caroline, Besse, Benjamin, Escande, Alexandre, Planchard, David, Le Péchoux, Cécile, Deutsch, Eric
發表在 PLoS One (2018)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

由 Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier
發表在 J Cachexia Sarcopenia Muscle (2019)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

由 Passaro, Antonio, Addeo, Alfredo, Von Garnier, Christophe, Blackhall, Fiona, Planchard, David, Felip, Enriqueta, Dziadziuszko, Rafal, de Marinis, Filippo, Reck, Martin, Bouchaab, Hasna, Peters, Solange
發表在 ESMO Open (2020)

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

由 Kas, Baptiste, Talbot, Hugues, Ferrara, Roberto, Richard, Colombe, Lamarque, Jean-Philippe, Pitre-Champagnat, Stéphanie, Planchard, David, Balleyguier, Corinne, Besse, Benjamin, Mezquita, Laura, Lassau, Nathalie, Caramella, Caroline
發表在 JAMA Oncol (2020)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

由 Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le
發表在 Oncotarget (2017)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

由 Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise
發表在 NPJ Precis Oncol (2021)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

由 Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
發表在 Invest New Drugs (2020)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

由 Park, Wungki, Mezquita, Laura, Okabe, Naoyuki, Chae, Young Kwang, Kwon, Deukwoo, Saravia, Diana, Auclin, Edouard, Planchard, David, Caramella, Caroline, Ferrara, Roberto, Agte, Sarita, Oh, Michael, Mudad, Raja, Jahanzeb, Mohammad, Suzuki, Hiroyuki, Besse, Benjamin, Lopes, Gilberto
發表在 Br J Cancer (2019)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

由 Remon, Jordi, Swalduz, Aurelie, Planchard, David, Ortiz-Cuaran, Sandra, Mezquita, Laura, Lacroix, Ludovic, Jovelet, Cecile, Rouleau, Etienne, Leonce, Camille, De Kievit, Frank, Morris, Clive, Jones, Greg, Mercier, Kelly, Howarth, Karen, Green, Emma, Pérol, Maurice, Saintigny, Pierre, Besse, Benjamin
發表在 PLoS One (2020)

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

由 Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E
發表在 Lancet Oncol (2016)